Previous 10 | Next 10 |
2024-05-29 10:18:39 ET More on Novo Nordisk, Catalent Catalent - Novo Holdings Merger: Attractive Spread Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Consid...
Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to appr...
2024-05-24 15:00:53 ET More on the markets S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards Stocks have more room to run - Invesco's Kristina Hooper Big bear Mike Wilson changes tune a...
2024-05-20 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-19 14:00:55 ET More on pharma companies Novo Nordisk, J&J lead R&D rankings in big pharma: report Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson: Buy This Bargain Before It's Gone ...
2024-05-19 01:40:13 ET Summary Top M&A stocks of the 32 funds I follow. US Steel, the top stock held by merger-focused funds. Juniper Networks the second top stock. The thing about merger arbitrage is that it is always changing. Sometimes it seems easy for deals ...
2024-05-16 07:29:48 ET Summary Although Avid is 30+ years old, the story has become much more exciting due to the shift to a pure-play biologics CDMO, pharma increasingly outsourcing biologics, and record revenue-generating capacity. Avid has an economic moat with its mission-crit...
2024-05-08 17:40:18 ET More on Catalent Catalent, Novo Nordisk receive FTC request for more information Catalent gains after filing 10-Q Seeking Alpha’s Quant Rating on Catalent Historical earnings data for Catalent Financial information for Ca...
Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency (1) , compared to Q3'23. Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3’23 and ~$60 million in Q3’24, increased 11% compared to Q3'23. Q3'24...
2024-05-03 09:26:24 ET More on Catalent Catalent - Novo Holdings Merger: Attractive Spread Catalent gains after filing 10-Q FTC likely to look at Catalent alternatives in review of Novo deal - report Seeking Alpha’s Quant Rating on Catalent His...
News, Short Squeeze, Breakout and More Instantly...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Catalent, Inc. (NYSE: CTLT) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 3.37% on the day to $56.66. Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologi...